Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27822820 | 0.81 | APP (0.42) | ALOX5CYP3A4MAOBNPC1MAOA | |
| SCHEMBL27802206 | 0.81 | MAOB (0.46) | ALOX5MAOBMAPTSMN1; SMN2RAB9A | |
| SCHEMBL2459600 | 0.78 | — | — | |
| SCHEMBL64412 | 0.78 | ALDH1A1 (0.34) | ALOX5L3MBTL1MAPTRAB9ANPC1 | |
| SCHEMBL28068013 | 0.77 | CYP3A4 (0.50) | ALOX5CYP3A4L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL3058689 | 0.77 | MAPT (0.50) | ALOX5L3MBTL1MAOBMAPTSMN1; SMN2 | |
| SCHEMBL2502936 | 0.75 | PTPN1 (0.33) | CYP1A2 | |
| SCHEMBL2214200 | 0.75 | ALDH1A1 (0.42) | MAPK1TDP1GAAIDO1 | |
| SCHEMBL1389283 | 0.75 | TLR8 (0.37) | L3MBTL1MAPTLMNATSHRMAPK1 | |
| SCHEMBL6538521 | 0.75 | KCNA3 (0.52) | HDAC6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1252042-C | Oximate light initiator | CIBA SC HOLDING AG (CH) | 2006-04-19 | — | — | CN | claimed |
| US-6949678-B2 | Oxime ester photoinitiators | CIBA SPECIALTY CHEMICALS CORP. (US) | 2005-09-27 | — | — | US | claimed |
| EP-1019046-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2002-11-27 | — | — | EP | claimed |
| US-20020049316-A1 | Protease inhibitors | HALBERT STACIE MARIE (US) | 2002-04-25 | — | — | US | claimed |
| EP-0802920-B1 | ANTIFUNGAL FUSACANDINS | ABBOTT LAB (US) | 2001-10-04 | — | — | EP | claimed |
| CN-1261276-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2000-07-26 | — | — | CN | claimed |
| EP-1019046-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1998048799-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | claimed |
| US-5773421-A | Antifungal fusacandins | ABBOTT LABORATORIES (US) | 1998-06-30 | — | — | US | claimed |
| US-5763436-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | claimed |
| US-5595999-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | claimed |
| US-5583133-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | claimed |
| WO-1996021670-A2 | ANTIFUNGAL FUSACANDINS | ABBOTT LABORATORIES (US) | 1996-07-18 | — | — | WO | claimed |
| US-5532232-A | INHIBIT THROMBIN INDUCED PLATELET AGGREGATION; FIBRINOGEN ANTICOAGULANTS IN BLOOD | HOFFMANN-LA ROCHE INC. (US) | 1996-07-02 | — | — | US | claimed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | claimed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | claimed |
| EP-0468231-B1 | Guanidins | HOFFMANN LA ROCHE (CH) | 1994-09-21 | — | — | EP | claimed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | claimed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | claimed |
| EP-0468231-A2 | Guanidins | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049316-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | ALOX5 1915/4885CYP3A4 1217/4885L3MBTL1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.